Rafael Martinez-Perez1, Luis C Requena1, Ricardo L Carrau1,2, Daniel M Prevedello3,4. 1. Departments of Neurosurgery, Wexner Medical Center, The Ohio State University, 410 W 10th Ave, Columbus, OH, 43210, USA. 2. Head and Neck Surgery, Wexner Medical Center, The Ohio State University, Columbus, OH, USA. 3. Departments of Neurosurgery, Wexner Medical Center, The Ohio State University, 410 W 10th Ave, Columbus, OH, 43210, USA. daniel.prevedello@osumc.edu. 4. Head and Neck Surgery, Wexner Medical Center, The Ohio State University, Columbus, OH, USA. daniel.prevedello@osumc.edu.
Abstract
INTRODUCTION: Since the early use of the endoscopic view for treating simple intrasellar pituitary adenomas, the skull base surgery has experienced an unprecedented revolution elevating the treatment of skull base lesions to the next level in proficiency and excellence of care. METHODS: We have reviewed the preclinical and clinical evidence supporting the use of the endoscope in the treatment of skull base lesions. In this article, we aim to discuss and provide a wide view of the current indications and future perspectives of the endoscopic endonasal approaches (EEA) and of the endoscopic transcranial approaches. RESULTS: As in the development of any other technique, EEA have gone through a transformation process from theoretical anatomic models to a pragmatic clinical use. Along the way, EEA have required several modifications, as well as pushbacks in the application of this technique in some indications. This process has resulted in the provision of an additional tool to the current surgical armamentarium that allows the skull base surgeon to face most challenging lesions along the skull base. CONCLUSIONS: The judicious combination of transcranial and endoscopic-transnasal approaches warrants highest chances of achieving satisfactory tumors resection with a reduced risk of complications.
INTRODUCTION: Since the early use of the endoscopic view for treating simple intrasellar pituitary adenomas, the skull base surgery has experienced an unprecedented revolution elevating the treatment of skull base lesions to the next level in proficiency and excellence of care. METHODS: We have reviewed the preclinical and clinical evidence supporting the use of the endoscope in the treatment of skull base lesions. In this article, we aim to discuss and provide a wide view of the current indications and future perspectives of the endoscopic endonasal approaches (EEA) and of the endoscopic transcranial approaches. RESULTS: As in the development of any other technique, EEA have gone through a transformation process from theoretical anatomic models to a pragmatic clinical use. Along the way, EEA have required several modifications, as well as pushbacks in the application of this technique in some indications. This process has resulted in the provision of an additional tool to the current surgical armamentarium that allows the skull base surgeon to face most challenging lesions along the skull base. CONCLUSIONS: The judicious combination of transcranial and endoscopic-transnasal approaches warrants highest chances of achieving satisfactory tumors resection with a reduced risk of complications.
Authors: Thiago Albonette-Felicio; Gustavo G Rangel; Rafael Martinéz-Pérez; Douglas A Hardesty; Ricardo L Carrau; Daniel M Prevedello Journal: J Neurooncol Date: 2020-02-04 Impact factor: 4.130
Authors: Gustavo Hadad; Luis Bassagasteguy; Ricardo L Carrau; Juan C Mataza; Amin Kassam; Carl H Snyderman; Arlan Mintz Journal: Laryngoscope Date: 2006-10 Impact factor: 3.325
Authors: Russell R Lonser; Joshua J Wind; Lynnette K Nieman; Robert J Weil; Hetty L DeVroom; Edward H Oldfield Journal: J Clin Endocrinol Metab Date: 2013-01-31 Impact factor: 5.958
Authors: Rafael Martinez-Perez; Michael W Kortz; William Florez-Perdomo; Timothy H Ung; A Samy Youssef Journal: Neurosurg Rev Date: 2022-02-12 Impact factor: 3.042
Authors: Giulia Guizzardi; Alberto Di Somma; Matteo de Notaris; Francesco Corrivetti; Juan Carlos Sánchez; Isam Alobid; Abel Ferres; Pedro Roldan; Luis Reyes; Joaquim Enseñat; Alberto Prats-Galino Journal: Front Oncol Date: 2022-09-02 Impact factor: 5.738